At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed metastatic or recurrent nasopharyngeal carcinoma
- ✓ECOG performance status ≤2
- ✓Age ≥18 years
- ✓At least one lesion safely amenable to irradiation, with prior radiation ≥6 months prior
- ✕Active brain metastases or leptomeningeal disease
- ✕Prior active malignancy within previous 3 years (except specific skin, bladder, prostate, breast, or cervix cancers)
- ✕Systemic corticosteroids >10mg daily prednisone equivalents within 14 days of study drug
- ✕Positive hepatitis B surface antigen or hepatitis C RNA
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04830267Phase 2RecruitingUpdate OverdueUpdated 27mo ago · Completion was 22mo agoA Phase II Randomized Trial of Camrelizumab With Stereotactic Body Radiotherapy Versus Camrelizumab Alone in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Camrelizumab and Stereotactic body radiotherapy for Nasopharyngeal Carcinoma. Currently recruiting, targeting 39 participants across 3 sites.
Signals
Detailed Summary
Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer. Stereotactic body radiotherapy is a potential immunostimulatory therapy that may amplify antitumor response when combined with camrelizumab.
Study Details
Timeline
Interventions
Camrelizumab 200mg IV starting day 1 and then every 2 weeks thereafter. Treatment with Camrelizumab will continue until progression or unacceptable toxicity.
Image guided, stereotactic body radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Camrelizumab).